Your browser doesn't support javascript.
loading
The Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder.
May, Tamara; Birch, Edwina; Chaves, Karina; Cranswick, Noel; Culnane, Evelyn; Delaney, Jane; Derrick, Maddi; Eapen, Valsamma; Edlington, Chantele; Efron, Daryl; Ewais, Tatjana; Garner, Ingrid; Gathercole, Michael; Jagadheesan, Karuppiah; Jobson, Laura; Kramer, John; Mack, Martha; Misso, Marie; Murrup-Stewart, Cammi; Savage, Evan; Sciberras, Emma; Singh, Bruce; Testa, Renee; Vale, Lisa; Weirman, Alyssa; Petch, Edward; Williams, Katrina; Bellgrove, Mark.
  • May T; Department of Paediatrics, Monash University, Clayton, VIC, Australia.
  • Birch E; ADHD Foundation, Epping, NSW, Australia.
  • Chaves K; Albury Wodonga Health, Albury, NSW, Australia.
  • Cranswick N; Clinical Pharmacology Unit, Department of Medicine and Melbourne Children's Trials Centre, Royal Children's Hospital, Parkville, Vic, Australia.
  • Culnane E; Murdoch Children's Research Institute, Parkville Vic, Australia.
  • Delaney J; University of Melbourne, Parkville, VIC, Australia.
  • Derrick M; The Royal Children's Hospital Melbourne, Parkville, VIC, Australia.
  • Eapen V; Speech Pathology Australia, Melbourne, VIC, Australia.
  • Edlington C; Hobart ADHD Consultants, Bellerive, TAS, Australia.
  • Efron D; South Western Sydney Local Health District and Ingham Institute for Applied Medical Research, UNSW Sydney, Liverpool, NSW, Australia.
  • Ewais T; Speech Pathology Australia, Melbourne, VIC, Australia.
  • Garner I; Murdoch Children's Research Institute, Parkville Vic, Australia.
  • Gathercole M; The Royal Children's Hospital Melbourne, Parkville, VIC, Australia.
  • Jagadheesan K; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia.
  • Jobson L; Faculty of Medicine, University of Queensland, Herston, QLD, Australia.
  • Kramer J; School of Medicine and Dentistry, Griffith University, Southport, QLD, Australia.
  • Mack M; ADHD Guideline Development Group, Melbourne, VIC, Australia.
  • Misso M; Youth Justice, Department of Community and Justice, Grafton, NSW, Australia.
  • Murrup-Stewart C; NWAMHS-North West Area Mental Health Services, Melbourne, VIC, Australia.
  • Savage E; Bi-National ADHD Network Committee, RANZCP - Royal Australian and New Zealand College of Psychiatrists, Melbourne, VIC, Australia.
  • Sciberras E; Swinburne University, Melbourne, VIC, Australia.
  • Singh B; Turner Institute for Brain and Mental Health and School of Psychological Sciences, Monash University, Clayton, VIC, Australia.
  • Testa R; ADHD, ASD and Neurodiversity Special Interest Group, Faculty of Special Interests, RACGP.
  • Vale L; Rural Medical School, UNSW Medicine & Health, Coffs Harbour, NSW, Australia.
  • Weirman A; Applied Neuroscience Society of Australasia (ANSA).
  • Petch E; The Knowledge Synthesis Lab, Melbourne, VIC, Australia.
  • Williams K; Turner Institute for Brain and Mental Health and School of Psychological Sciences, Monash University, Clayton, VIC, Australia.
  • Bellgrove M; Department of Education, VIC, Australia.
Aust N Z J Psychiatry ; 57(8): 1101-1116, 2023 08.
Article en En | MEDLINE | ID: mdl-37254562
ABSTRACT

OBJECTIVE:

The objective of this article was to provide an overview of the development and recommendations from the Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder (ADHD). The guideline aims to promote accurate and timely identification and diagnosis, and optimal and consistent treatment of ADHD.

METHODS:

Development integrated the best available evidence with multidisciplinary clinical expertise and the preferences of those with lived experience, underpinned by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The 23 guideline development group members included psychiatrists, paediatricians, general practitioners, psychologists, speech pathologists, occupational therapists, educators, Indigenous psychologists, and people with a lived experience; with two independent chairs and a methodologist. Where appropriate, evidence reviews from the National Institute for Health and Care Excellence (NICE) 2018 'Attention Deficit Hyperactivity Disorder Diagnosis and Management' guideline were updated. Fifty prioritised clinical questions were addressed in 14 systematic reviews (new and updated from NICE 2018) and 28 narrative reviews.

RESULTS:

The 113 clinical recommendations apply to young children (5 years and under), children, adolescents and adults. They provide guidance for clinicians on identification, screening, diagnosis, multimodal treatment and support, including pharmacological and non-pharmacological interventions. The guideline and supporting information are available online https//adhdguideline.aadpa.com.au/.

CONCLUSIONS:

The guideline was approved by the National Health and Medical Research Council (NHMRC) of Australia and relevant medical and allied health professional associations. It is anticipated that successful implementation and uptake of the guideline by organisations, health care providers and other professionals will increase delivery of evidence-based treatment and improve health outcomes for the more than 800,000 Australians with ADHD.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psiquiatría / Trastorno por Déficit de Atención con Hiperactividad / Médicos Generales Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Adolescent / Adult / Child / Child, preschool / Humans País como asunto: Oceania Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psiquiatría / Trastorno por Déficit de Atención con Hiperactividad / Médicos Generales Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Adolescent / Adult / Child / Child, preschool / Humans País como asunto: Oceania Idioma: En Año: 2023 Tipo del documento: Article